PD-L2/CD273 Polyclonal antibody

PD-L2/CD273 Polyclonal Antibody for WB, ELISA

Host / Isotype

Rabbit / IgG


human, mouse, rat





Cat no : 18251-1-AP


B7 DC, Btdc, Butyrophilin B7 DC, CD273, PD 1 ligand 2, PDCD1 ligand 2, PDCD1L2, PDCD1LG2, PDL2, PD-L2, PD-L2/CD273, Programmed death ligand 2

Tested Applications

Positive WB detected inmouse heart tissue, HepG2 cells, RAW 264.7 cells

Recommended dilution

Western Blot (WB)WB : 1:200-1:1000
Sample-dependent, check data in validation data gallery

Product Information

The immunogen of 18251-1-AP is PD-L2/CD273 Fusion Protein expressed in E. coli.

Tested Reactivity human, mouse, rat
Cited Reactivityhuman, mouse
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen PD-L2/CD273 fusion protein Ag13039
Full Name programmed cell death 1 ligand 2
Calculated molecular weight 273 aa, 31 kDa
Observed molecular weight 42 kDa, 28 kDa
GenBank accession numberBC074766
Gene symbol PDCD1LG2
Gene ID (NCBI) 80380
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

Programmed cell death ligand 2 (PD-L2, also known as CD273, or B7-DC), is one of the B7 family molecules which are type I transmembrane proteins belonging to the immunoglobulin superfamily. PD-L2 was identified both by its homology to PD-L1 and by analysis of genes differentially expressed in libraries generated from dendritic cells (DC) and activated macrophages (PMID: 14515254). PD-L2 is a second ligand for PD-1, a costimulatory molecule that plays an inhibitory role in regulating T cell activation in the periphery.


Product Specific Protocols
WB protocol for PD-L2/CD273 antibody 18251-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols



Aging Cell

Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression.

Authors - Qixia Xu

Cancer Sci

ANO9 regulates PD-L2 expression and binding ability to PD-1 in gastric cancer.

Authors - Keita Katsurahara

J Cell Mol Med

IFI30 expression is an independent unfavourable prognostic factor in glioma.

Authors - Xiu Liu

J Transl Med

Treatment with eFT-508 increases chemosensitivity in breast cancer cells by modulating the tumor microenvironment.

Authors - Zhao-Ying Yang

Oncol Rep

Differential expression of PD‑L1 and PD‑L2 is associated with the tumor microenvironment of TILs and M2 TAMs and tumor differentiation in non‑small cell lung cancer.

Authors - Ryota Sumitomo

Urol Oncol

Programmed death-ligand 2 (PD-L2) expression in bladder cancer.

Authors - Yubo Yang